CEO Christian Clausen’s comments on the results: “The second quarter of 2014 was characterised by a continued inflow of customers and strong activity, particularly in our savings area and corporate advisory business. Income is holding up well, despite low lending demand, low interest rates and low volatility, and we continue to execute on our cost and capital efficiency programmes. Underlying costs are down in local currencies and cost to income ratio is 49%. The Common equity tier 1 capital ratio improved by 60 basis points to 15.2%. We are proud that still more households and corporates trust us with their banking business and savings. Our sector is transforming, with swiftly changing customer behaviour in the direction of using services and receiving advice online. We continue the work of adapting to the new demands to earn our customers’ trust as a relationship bank also in the future.” (For further viewpoints, see CEO comments, page 2) First half year 2014 vs. First half year 2013 (Second quarter 2014 vs. First quarter 2014)¹: · Total operating income -1%, in local currencies +2% (-2%) · Total expenses -4% excluding restructuring costs, in local currencies 0% ( -3%) · Total expenses +4% including restructuring costs of EUR 190m in the second quarter (+12%) · Operating profit +7%¹, in local currencies +10%¹ (+2%¹) · Common equity tier 1 capital ratio 15.2%, up from 13.1%² (up to 15.2% from 14.6%) · Cost/income ratio down to 49%¹ from 51% (down 0.8 %-point to 49%¹) · Loan loss ratio of 17 basis points, down from 23 basis points (down to 16 bps from 18 bps) · Return on equity 11.7%¹, up from 11.3% (up to 12.0%¹ from 11.4%) +------------+-----+-----+---+-----+---+--------+-----+-----+---+--------+ |Summary key | Q2| Q1| ch| Q2| ch|loc.curr| H1| H1| ch|loc.curr| |figures, | 2014| 2014| %| 2013| %| Q2/Q2 %| 2014| 2013| %| H1/H1 %| |continuing | | | | | | | | | | | |operations³,| | | | | | | | | | | |EURm | | | | | | | | | | | +------------+-----+-----+---+-----+---+--------+-----+-----+---+--------+ |Net interest|1,368|1,362| 0|1,391| -2| 1|2,730|2,749| -1| 3| |income | | | | | | | | | | | +------------+-----+-----+---+-----+---+--------+-----+-----+---+--------+ |Total |2,456|2,501| -2|2,490| -1| 1|4,957|4,996| -1| 2| |operating | | | | | | | | | | | |income | | | | | | | | | | | +------------+-----+-----+---+-----+---+--------+-----+-----+---+--------+ |Profit |1,070|1,264|-15|1,234|-13| -11|2,334|2,473| -6| -3| |before loan | | | | | | | | | | | |losses | | | | | | | | | | | +------------+-----+-----+---+-----+---+--------+-----+-----+---+--------+ |Net loan | -135| -158|-15| -186|-27| -26| -293| -384|-24| -22| |losses | | | | | | | | | | | +------------+-----+-----+---+-----+---+--------+-----+-----+---+--------+ |Loan loss | 16| 18| | 22| | | 17| 23| | | |ratio | | | | | | | | | | | |(ann.), | | | | | | | | | | | |bps | | | | | | | | | | | +------------+-----+-----+---+-----+---+--------+-----+-----+---+--------+ |Operating |1,125|1,106| 2|1,048| 7| 10|2,231|2,089| 7| 10| |profit¹ | | | | | | | | | | | +------------+-----+-----+---+-----+---+--------+-----+-----+---+--------+ |Operating | 935|1,106|-15|1,048|-11| -8|2,041|2,089| -2| 1| |profit | | | | | | | | | | | +------------+-----+-----+---+-----+---+--------+-----+-----+---+--------+ |Risk | 876| 880| 0| 853| 3| 6|1,756|1,707| 3| 6| |-adjusted | | | | | | | | | | | |profit¹ | | | | | | | | | | | +------------+-----+-----+---+-----+---+--------+-----+-----+---+--------+ |Diluted EPS | 0.18| 0.21| | 0.20| | | 0.39| 0.39| | | |(cont. | | | | | | | | | | | |oper.), EUR | | | | | | | | | | | +------------+-----+-----+---+-----+---+--------+-----+-----+---+--------+ |Diluted EPS | 0.17| 0.21| | 0.19| | | 0.38| 0.39| | | |(total | | | | | | | | | | | |oper.), EUR | | | | | | | | | | | +------------+-----+-----+---+-----+---+--------+-----+-----+---+--------+ |Return on | 12.0| 11.4| | 11.5| | | 11.7| 11.3| | | |equity¹, % | | | | | | | | | | | +------------+-----+-----+---+-----+---+--------+-----+-----+---+--------+ |Return on | 10.0| 11.4| | 11.5| | | 10.7| 11.3| | | |equity, % | | | | | | | | | | | +------------+-----+-----+---+-----+---+--------+-----+-----+---+--------+ Exchange rates used for Q2 2014 for income statement items are for DKK 7.46, NOK 8.28 and SEK 8.96, see also Note 1. Net impact from currency fluctuations between Q2 2014 and Q1 2014 was insignificant. ¹) Excluding restructuring costs in Q2 2014 of EUR 190m. ²) Previously estimated CET1 ratio. ³) Key figures for continuing operations, following the divestment of the Polish banking, financing and life insurance operations. For further information: Christian Clausen, President and Group CEO, +46 8 614 7804 Torsten Hagen Jørgensen, Group CFO, +46 8 614 7814 Rodney Alfvén, Head of Investor Relations, +46 72 235 05 15 Claus Christensen, Head of Group Identity & Communications, +45 25248993 Go to IR Report pages (http://www.nordea.com/Investor+Relations/Financial+reports/Interim+report s /804972.html) The information provided in this press release is such that Nordea is required to disclose pursuant to the Swedish Financial Instruments Trading Act (1991:980) and/or the Swedish Securities Markets Act (2007:528).
Second Quarter Results 2014 CEO Christian Clausen’s
Top 10 Most Recent News Articles
CVS Study: GLP-1 Drugs Effective But Costly
Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...
Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit
A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...
Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations
ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...
Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West
Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...
Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control
Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...
Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact
A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...
Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup
An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....
Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined
Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...
Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms
Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...
Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss
Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...
Continue ReadingTop 5 Most Recently Viewed Articles
Exploring AI's Impact on CRM Visibility and Brand Trust
Understanding the Role of AI in CRM Visibility Brandi AI has recently launched its AI Visibility Index series, which offers insightful measurements of how industries are perceived in AI-generated responses. This new series highlights the ways in which customer relationship management (CRM) brands are represented through the lens of advanced AI answer engines. The AI...
Continue Reading
Celldex Therapeutics Thrives Amid Developments with Briquilimab
Overview of Celldex Therapeutics and Briquilimab Celldex Therapeutics (NASDAQ: CLDX) is navigating an exciting phase as it explores treatments for chronic conditions like Chronic Inducible Urticaria (CIndU). Analysts have closely observed the efficacy of briquilimab, highlighting its performance through recent studies. Analyst Insights on Celldex and Briquilimab Goldman...
Continue Reading
XPENG's Financial Success in Q3 2024: Key Insights Revealed
XPENG's Journey in the Third Quarter of 2024 XPeng Inc. (“XPENG” or “the Company,” NYSE: XPEV and HKEX: 9868) recently disclosed its financial results for the third quarter ended September 30, 2024. This marks a significant period showcasing growth in revenues and vehicle deliveries, reflecting the company's robust strategy in the smart electric vehicle market....
Continue Reading
Apple Inc. Beats Earnings Expectations: Analysts React
Apple Inc. Overcomes Challenges with Strong Quarterly Results Apple Inc.‘s latest quarterly performance has generated significant buzz in the tech world. Analysts reveal that the results showcase a resilient company navigating through various market challenges. This performance not only reflects strong sales of products like the iPhone but also highlights impressive...
Continue Reading
Class Action Alert: Investors Have Rights with AMMO, Inc.
Class Action Lawsuit Against AMMO, Inc. In a proactive move for investors, Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against AMMO, Inc. (NASDAQ: POWW). This suit comes in light of significant losses experienced by investors in the company due to alleged misstatements and omissions regarding its business practices. Understanding the Class...
Continue Reading